http://avelient.com/BioPharmBlog/2007/06/12/weight-loss-is-there-a-magic-pill/ A blog on Biotech, the Pharmaceutical industry, and Personal Health Wed, 07 Jan 2009 13:45:12 +0000 http://wordpress.org/?v=2.6.5 http://avelient.com/BioPharmBlog/2007/06/12/weight-loss-is-there-a-magic-pill/#comment-1049 Avelient BioPharm Blog » The Pipeline Floodeth Wed, 19 Dec 2007 16:15:54 +0000 http://avelient.com/BioPharmBlog/?p=9#comment-1049 [...] At several points during the year, I wrote about Sanofi-Aventis‘ drug Acomplia, a controversial weight-loss drug that had potential major side-effects, including anxiety, insomnia and depression. The first time I had written about the drug, it was being considered for approval by the FDA in the United States. Since then, an advisory panel rejected its approval here, but Sanofi-Aventis apparently hasn’t given up, according to the report. [...] [...] At several points during the year, I wrote about Sanofi-Aventis‘ drug Acomplia, a controversial weight-loss drug that had potential major side-effects, including anxiety, insomnia and depression. The first time I had written about the drug, it was being considered for approval by the FDA in the United States. Since then, an advisory panel rejected its approval here, but Sanofi-Aventis apparently hasn’t given up, according to the report. [...]

]]> http://avelient.com/BioPharmBlog/2007/06/12/weight-loss-is-there-a-magic-pill/#comment-625 Avelient BioPharm Blog » FDA Balancing Act Sat, 17 Nov 2007 03:01:51 +0000 http://avelient.com/BioPharmBlog/?p=9#comment-625 [...] Sanofi-Aventis’ Acomplia, intended to fight obesity, got an approvable letter from the FDA in 2006 but then was given an unfavorable review from an FDA advisory committee in June this year prompting the French firm to withdraw its NDA. For more information on this, you can see the 2 articles I wrote about the drug here, before the FDA released its findings and here, after the FDA released its findings. [...] [...] Sanofi-Aventis’ Acomplia, intended to fight obesity, got an approvable letter from the FDA in 2006 but then was given an unfavorable review from an FDA advisory committee in June this year prompting the French firm to withdraw its NDA. For more information on this, you can see the 2 articles I wrote about the drug here, before the FDA released its findings and here, after the FDA released its findings. [...]

]]>